Differential regulations of lipid profiles between Japanese responders and nonresponders treated with pioglitazone

Postgraduate Medicine

Volumn 123, Issue 1, 2011, Pages 45-52

  Kutoh, Eiji ^a,b  

^a Biomedical Center   (Japan)

^b Gyoda General Hospital   (Japan)

Author keywords

Cholesterol; Diabetes; Dyslipidemia; Insulin resistance; Lipid levels; Pioglitazone

Indexed keywords

CHOLESTEROL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN;

ADULT; ANALYSIS OF COVARIANCE; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GLYCEMIC CONTROL; HUMAN; JAPANESE; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; SIDE EFFECT; UPREGULATION; WEIGHT GAIN; AGED; BLOOD; JAPAN; MIDDLE AGED;

ADULT; AGED; BODY MASS INDEX; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; LIPIDS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES; TRIGLYCERIDES;

EID: 79952807947     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2011.01.2244     Document Type: Article

References (29)

1. Betteridge DJ. CHICAGO, PERISCOPE and PROactive: CV risk modification in diabetes with pioglitazone. Fundam Clin Pharmacol. 2009;23(6):675-679.
2. Bloomgarden ZT. Thiazolidinediones. Diabetes Care. 2005;28(2): 488-493.
3. Tajiri Y, Takei R, Mimura K, Umeda F. Indicators for the efficacy of pioglitazone before and during treatment in Japanese patients with type 2 diabetes. Diabetes Technol Ther. 2007;9(5):429-437.
4. Igarashi M, Jimbu Y, Kimura M, Hirata A, Yamaguchi H, Tominaga M. Effect of pioglitazone on atherogenic outcomes in type 2 diabetic patients: a comparison of responders and non-responders. Diabetes Res Clin Pract. 2007;77(3):389-398.
5. Stumvoll M, Häring H. The peroxisome proliferator-activated receptorgamma2 Pro12Ala polymorphism. Diabetes. 2002;51(8):2341-2347.
6. Buse JB, Tan MH, Prince MJ, Erickson PP. The effects of oral antihyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab. 2004;6(2):133-156.
7. Dormandy JA, Charbonnel B, Eckland DJ, et al; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279-1289.
8. Parhofer KG, Otto C, Geiss HC, Laubach E, Göke B. Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus type 2-results of a pilot study. Exp Clin Endocrinol Diabetes. 2005;113(1):49-52.
9. Gegick CG, Altheimer MD. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocr Pract. 2001;7(3):162-169.
10. Olansky L, Marchetti A, Lau H. Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: comparative subgroup analyses of glycemic control and blood lipid levels. Clin Ther. 2003;25(suppl B):B64-B80.
11. Nakayama T, Komiyama N, Yokoyama M, et al. Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound. Int J Cardiol. 2010;138(2):157-165.
12. Nissen SE, Nicholls SJ, Wolski K, et al; PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299(13):1561-1573.
13. Ballantyne CM, Raichlen JS, Nicholls SJ, et al; ASTEROID Investigators. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation. 2008;117(19):2458-2466.
14. Stein EA. Managing dyslipidemia in the high-risk patient. Am J Cardiol. 2002;89(5A):50C-57C.
15. Brunzell JD, Davidson M, Furberg CD, et al; American Diabetes Association; American College of Cardiology. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care. 2008;31(4):811-822.
16. Liu J, Sempos CT, Donahue RP, Dorn J, Trevisan M, Grundy SM. Nonhigh- density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. Am J Cardiol. 2006;98(10):1363-1368.
17. Tominaga M. Diagnostic criteria for diabetes mellitus. Rinsho Byori. 1999;47(10):901-908.
18. Wang G, Wang X, Zhang Q, Ma Z. Response to pioglitazone treatment is associated with the lipoprotein lipase S447X variant in subjects with type 2 diabetes mellitus. Int J Clin Pract. 2007;61(4):552-557.
19. Feinböck C, Luger A, Klingler A, et al; Austrian Glimepiride Study Group. Prospective multicentre trial comparing the efficacy of, and compliance with, glimepiride or acarbose treatment in patients with type 2 diabetes not controlled with diet alone. Diabetes Nutr Metab. 2003;16(4):214-221.
20. Gavin LA, Barth J, Arnold D, Shaw R. Troglitazone add-on therapy to a combination of sulfonylureas plus metformin achieved and sustained effective diabetes control. Endocr Pract. 2000;6(4):305-310.
21. Kurabayashi M, Yamazaki T; SUBARU Study Group. Superior benefit of aggressive lipid-lowering therapy for high-risk patients using statins: the SUBARU study-more hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin therapy. J Atheroscler Thromb. 2008;15(6):314-323.
22. Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care. 2006;29(9): 2137-2139.
23. Betteridge DJ. Effects of pioglitazone on lipid and lipoprotein metabolism. Diabetes Obes Metab. 2007;9(5):640-647.
24. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med. 2004;164(19):2097-2104.
25. Nathan DM. Some answers, more controversy, from UKPDS. United Kingdom Prospective Diabetes Study. Lancet. 1998;352(9131): 832-833.
26. Berkenstam A, Gustafsson JA. Nuclear receptors and their relevance to diseases related to lipid metabolism. Curr Opin Pharmacol. 2005;5(2):171-176.
27. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med. 2004;10(4):355-361.
28. Teramoto T, Shimano H, Yokote K, Urashima M. New evidence on pitavastatin: efficacy and safety in clinical studies. Expert Opin Pharmacother. 2010;11(5):817-828.
29. Karalis IK, Bergheanu SC, Wolterbeek R, et al. Effect of increasing doses of Rosuvastatin and Atorvastatin on apolipoproteins, enzymes and lipid transfer proteins involved in lipoprotein metabolism and inflammatory parameters. Curr Med Res Opin. 2010;26(10):2301-2313.